New Efficacy Data For RCC From KEYNOTE-B61 Added To Lenvima® (Lenvatinib) US Label Supporting Keytruda + Lenvima Indication For The 1L Treatment July 1, 2024
MHRA approves expansion of ModiFY trial; Modi-1 to be assessed in RCC in combination with double CPIs May 31, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
$15 million CIRM Grant Supports the Ongoing Ph 1 TRAVERSE Trial of ALLO-316 in Patients with Advanced or Metastatic RCC May 1, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy February 26, 2024
SC Nivolumab Shows Noninferiority Compared to IV Opdivo (nivolumab) in Advanced or Metastatic ccRCC in CheckMate -67T Trial February 26, 2024
Opdivo + CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC January 31, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy January 31, 2024
Enrollment of Ph 2/3 Trial of Fruquintinib + Sintilimab for Advanced RCC in China completed December 19, 2023
FDA Approves WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 19, 2023
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced RCC December 11, 2023
HiberCell and Merck to Evaluate HC-7366 + WELIREG (belzutifan) in Ph 1b Study of ccRCC Patients December 11, 2023
KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With RCC Following Nephrectomy November 7, 2023
Ph 3 CheckMate-67T Trial of SC Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced/Metastatic ccRCC October 25, 2023
FDA Accepts for Priority Review Supplemental NDA for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced RCC October 11, 2023
FDA Accepts for Priority Review Supplemental NDA for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced RCC September 26, 2023
WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC August 23, 2023
FDA Grants Fast Track designation to IVS-3001 for the Treatment of Renal Cell Carcinoma August 2, 2023
Enrollment completed in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma July 5, 2023
KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced RCC May 31, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
FAILED TRIAL: Ph 3 CONTACT-03 study of cabozantinib + atezolizumab versus cabozantinib alone in RCC patients did not meet primary endpoint of PFS March 15, 2023
Opdivo® + CABOMETYX® shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC February 22, 2023
